Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, ZKO will be responsible for clinical development and regulatory approval for BRIMOCHOL PF and Carbachol PF in the specified territories, and subsequently the commercialization activities for the products.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Visus Therapeutics
Deal Size: $130.0 million Upfront Cash: $15.0 million
Deal Type: Licensing Agreement May 11, 2022